SHIFT Newsroom · GLOBAL
Body composition and bone measures in a small type 1 diabetes cohort
An observational study followed seventy people with obesity and type 1 diabetes receiving liraglutide, semaglutide or tirzepatide over twelve months.
An observational study followed seventy people with obesity and type 1 diabetes receiving liraglutide, semaglutide or tirzepatide over twelve months. Weight, fat mass and lean mass declined; total bone mineral density did not significantly change. This small observational cohort cannot establish comparative medicine effects or long-term fracture safety. It is not a reason to replace insulin or change diabetes treatment without the specialist team.
SHIFT’s take
Read the study design and limits alongside the finding. This article does not determine individual treatment suitability.